4541.T Живые сигналы | Максимизируйте прибыль с Getagraph.com

Live Chart Being Loaded With Signals

Commentary (28 март 2023 @ 09:15):

Nichi-Iko Pharmaceutical Co., Ltd. manufactures, sells, imports, and distributes various pharmaceutical products. The company operates through two segments, Sagent Group and Nichi-Iko Group...

Stats
Объем за сегодня	5.21M
Средний объем	4.06M
Рыночная капитализация	2.47B
EPS	¥0 ( 2023-05-11 )
Last Dividend	¥10.00 ( 2022-03-30 )
Next Dividend	¥0 ( N/A )
P/E	0.0000000
ATR14	¥4.97 (0.00%)

Объем Корреляция

Длинно: -0.06 (neutral)

Кратко: -0.73 (moderate negative)

Signal:(100) Neutral

Nichi-Iko Pharmaceutical Корреляция

10 Самые положительные корреляции

10 Самые отрицательные корреляции

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

Nichi-Iko Pharmaceutical Корреляция - Валюта/Сырье

-0.01
( neutral )

-0.05
( neutral )

0.00
( neutral )

-0.08
( neutral )

0.28
( neutral )

0.13
( neutral )

Nichi-Iko Pharmaceutical Финансовые показатели

Annual	2022
Выручка:	¥16 907.73B
Валовая прибыль:	¥3 331.59B (19.70 %)
EPS:	¥128.01

FY	2022
Выручка:	¥16 907.73B
Валовая прибыль:	¥3 331.59B (19.70 %)
EPS:	¥128.01

FY	2022
Выручка:	¥179.06B
Валовая прибыль:	¥3.97B (2.21 %)
EPS:	¥-1 500.00

FY	2021
Выручка:	¥188.22B
Валовая прибыль:	¥21.25B (11.29 %)
EPS:	¥-65.28

Financial Reports:

No articles found.

Nichi-Iko Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

Nichi-Iko Pharmaceutical Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 9.48 - good (94.76%) | Divividend Growth Potential Score: 2.03 - No dividend growth expected in the near future

Information

First Dividend	¥12.00	2008-05-27
Last Dividend	¥10.00	2022-03-30
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	29	--
Total Paid Out	¥380.90	--
Avg. Dividend % Per Year	0.00%	--
Score	3.02	--
Div. Sustainability Score	9.48
Div.Growth Potential Score	2.03
Div. Directional Score	5.75	--

Next Divdend (Est)
(2024-06-10)

¥0 Estimate 0.00 %

Dividend Stability

0.10 Very Bad

Dividend Score

3.02

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
8537.T	Ex Dividend Junior	2023-09-28	Semi-Annually	0.00%
7860.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
7003.T	Ex Dividend Junior	2024-03-28	Sporadic	0.00%
6356.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
5210.T	Ex Dividend Knight	2024-03-28	Annually	0.00%
4318.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
3482.T	Ex Dividend Junior	2023-12-28	Annually	0.00%
2695.T	Ex Dividend Junior	2023-10-30	Annually	0.00%
9605.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
8151.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0400	1.500	9.20	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0137	1.200	9.54	10.00	[0 - 0.3]
returnOnEquityTTM	0.0717	1.500	-0.315	-0.472	[0.1 - 1]
payoutRatioTTM	0.555	-1.000	4.45	-4.45	[0 - 1]
currentRatioTTM	1.440	0.800	7.80	6.24	[1 - 3]
quickRatioTTM	0.617	0.800	-1.074	-0.859	[0.8 - 2.5]
cashRatioTTM	0.584	1.500	7.86	10.00	[0.2 - 2]
debtRatioTTM	0.185	-1.500	6.92	-10.00	[0 - 0.6]
interestCoverageTTM	92.82	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	119.18	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	86.82	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.474	-1.500	8.11	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.202	1.000	9.97	9.97	[0.2 - 0.8]
operatingProfitMarginTTM	0.0414	1.000	-1.172	-1.172	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.121	1.000	-0.438	-0.438	[0.2 - 2]
assetTurnoverTTM	0.344	0.800	-1.042	-0.833	[0.5 - 2]
Total Score				9.48

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	0.478	1.000	-0.0527	0	[1 - 100]
returnOnEquityTTM	0.0717	2.50	-0.202	-0.472	[0.1 - 1.5]
freeCashFlowPerShareTTM	86.82	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	119.18	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0.555	1.500	4.45	-4.45	[0 - 1]
pegRatioTTM	0.00441	1.500	-3.30	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0651	1.000	-0.872	0	[0.1 - 0.5]
Total Score				2.03

Nichi-Iko Pharmaceutical

Nichi-Iko Pharmaceutical Co., Ltd. manufactures, sells, imports, and distributes various pharmaceutical products. The company operates through two segments, Sagent Group and Nichi-Iko Group. It primarily focuses on the production of generic drugs. The company offers antidiabetic agents, antacids, antireflux agents, beta-blocker, hypnotic and sedative, angiotensin ? antagonist, angiotensin ? antagonist/diuretic combination, dyslipidaemic agent, and calcium antagonist products. It also provides treatments for circulatory, digestive, respiratory, central and peripheral nervous systems, and others. In addition, the company engages in the packaging design business. Further, it exports its products. The company was formerly known as Nihon Iyakuhin Kogyo Co., Ltd. and changed its name to Nichi-Iko Pharmaceutical Co., Ltd. in 2005. Nichi-Iko Pharmaceutical Co., Ltd. was incorporated in 1947 and is headquartered in Toyama, Japan.